Novel Lupus Drugs Continue to Shine in Extended Early Data

Two investigational lupus drugs demonstrated continued positive results in follow-on studies after showing encouraging primary phase II outcomes. The Toll-like receptor (TLR) inhibitor enpatoran maintained efficacy without diminution in extended data.